-
UK counter-terrorism unit probes rappers Kneecap but music stars back band
-
Yamal heroics preserve Barca Champions League final dream
-
2026 T20 World Cup 'biggest women's cricket event in England' - ECB
-
Bangladesh begins three days of mass political rallies
-
Children learn emergency drills as Kashmir tensions rise
-
Millions of children to suffer from Trump aid cuts
-
Veteran Wallaby Beale set for long-awaited injury return
-
Syria's Druze take up arms to defend their town against Islamists
-
Tesla sales plunge further in France, down 59% in April
-
US calls on India and Pakistan to 'de-escalate'
-
Israel reopens key roads as firefighters battle blaze
-
Europe far-right surge masks divisions
-
James will mull NBA future after Lakers playoff exit
-
Ukraine's chief rabbi sings plea to Trump to side with Kyiv
-
Australian mushroom meal victim 'hunched' in pain, court hears
-
Lakers dumped out of playoffs by Wolves, Rockets rout Warriors
-
Booming tourism and climate change threaten Albania's coast
-
US reaching out to China for tariff talks: Beijing state media
-
Tariffs prompt Bank of Japan to lower growth forecasts
-
Kiss faces little time to set Wallabies on path to home World Cup glory
-
Serbian students, unions join forces for anti-corruption protest
-
Slow and easily beaten -- Messi's Miami project risks global embarrassment
-
Fan in hospital after falling to field at Pirates game
-
Nuclear power sparks Australian election battle
-
Tokyo stocks rise as BoJ holds rates steady
-
Bank of Japan holds rates, lowers growth forecasts
-
'Sleeping giants' Bordeaux-Begles awaken before Champions Cup semis
-
Napoli eye Scudetto as Inter hope for post-Barca bounce-back
-
Germany's 'absolutely insane' second tier rivalling Europe's best
-
PSG minds on Arsenal return as French clubs scrap for Champions League places
-
UK WWII veteran remembers joy of war's end, 80 years on
-
Myanmar junta lets post-quake truce expire
-
Rockets romp past Warriors to extend NBA playoff series
-
Messi, Inter Miami CONCACAF Cup dream over as Vancouver advance
-
UN body warns over Trump's deep-sea mining order
-
UK local elections test big two parties
-
US judge says Apple defied order in App Store case
-
Seventeen years later, Brood XIV cicadas emerge in US
-
Scorching 1,500m return for Olympic great Ledecky in Florida
-
Israel's Netanyahu warns wildfires could reach Jerusalem
-
Istanbul lockdown aims to prevent May Day marches
-
Moderna Reports First Quarter 2025 Financial Results and Provides Business Updates
-
DEA Unconstitutional Marijuana Hearing - MMJ to File Emergency Injunction and Suit for Irreparable Harm
-
Formation Metals Announces Appointment of Adrian Smith to Advisory Committee
-
Cerrado Gold Announces Q4 And Annual 2024 Financial Results
-
Australian guard Daniels of Hawks named NBA's most improved
-
Mexico City to host F1 races until 2028
-
Morales vows no surrender in bid to reclaim Bolivian presidency
-
Ukraine, US sign minerals deal, tying Trump to Kyiv
-
Phenomenons like Yamal born every 50 years: Inter's Inzaghi
Conflicting US rulings leave fate of abortion pill in doubt
Conflicting rulings by two federal judges have left the future of abortion pills in the United States deeply uncertain, likely placing the divisive issue squarely in the lap of the Supreme Court.
A ruling Friday by federal judge Matthew Kacsmaryk in Texas banned the widely used drug mifepristone (RU 486) nationwide, boosting conservatives' efforts to further restrict abortion rights after the Supreme Court last year allowed states to prohibit them.
The unprecedented rejection of a drug approved in 2000 by the US Food and Drug Administration (FDA) -- and found safe by scientific consensus -- sparked outrage on the political left.
Kacsmaryk, in his ruling, adopted language used by abortion opponents, referring to abortion providers as "abortionists" and saying the drug was used to "kill the unborn human."
His ruling brought an immediate vow from the Biden administration and the drug's maker to appeal the matter in federal court.
Attorney General Merrick Garland said the Justice Department would ask the appeals court to stay the ban by Kacsmaryk, an ultraconservative Donald Trump appointee, until the case is finally resolved.
If the Texas ruling holds, it would complicate matters not just in the states now banning or sharply limiting abortions, but also in those where the procedure remains legal.
- Widely used -
Mifepristone has been used as part of a two-drug regimen by 5.6 million women since 2000.
But adding to the uncertainty and increasing the odds the matter ends up before the Supreme Court was a contradictory ruling from a Washington state judge that came just hours after Kacsmaryk's.
District Judge Thomas Rice, a Barack Obama appointee, ruled in a separate case -- brought by several states where abortion is legal -- that mifepristone is "safe and legal" and that the FDA must preserve access to it in more than a dozen states.
For now the drug remains legal, Alexis McGill Johnson, the head of Planned Parenthood, one of the largest pro-abortion groups in the country, said Friday.
Several abortion clinics also said Friday that they would continue using mifepristone until ordered not to by the FDA, US media reported.
Kacsmaryk paused the effect of his ruling for a week, allowing time for the administration and drugmaker Danco Laboratories to file before the US Fifth Circuit Court of Appeals in Louisiana, which hears cases from Texas.
The Justice Department is still reviewing Rice's ruling, Garland said in a statement.
- 'Remains safe' -
Given the sharply conflicting court rulings, the Justice Department might opt to take the case directly to the Supreme Court and not wait for the Fifth Circuit to act.
The high court could decide to take up the case on an emergency basis, which would require making room in an already crowded agenda at the end of the current term.
In that case, the court -- with six conservative justices outnumbering the three liberals -- could hear the case within days, or weeks, but sometime before the current session ends on June 30.
Chief Justice John Roberts, a conservative, is deeply protective of the image of the institution, and he might be expected to vote with the three liberals in favor of mifepristone. The additional vote of one other conservative could provide a majority for the drug.
The court's ruling last June to overturn the longstanding Roe v. Wade decision protecting abortion rights shifted considerable attention to medication abortions.
Most of them involve mifepristone in a two-drug regimen. A patient first takes a mifepristone pill to end the pregnancy, then a day later takes the drug misoprostol to induce contractions that expel the embryo or fetus.
Misoprostol can be used on its own to cause abortions, but the two-step procedure is considered more effective and can be more painful.
More than half of abortions in the US are done with medication.
Kacsmaryk, in his ruling, said the two-drug regimen had resulted in "thousands of adverse events suffered by women and girls," including intense bleeding and psychological trauma.
But the FDA, researchers and the drugmaker say decades of experience have proven the medication to be safe and effective.
Michigan Governor Gretchen Whitmer, a Democrat, tweeted:
"Despite this ruling, I want to be clear: abortion, including medication abortion, remains safe and legal in the state of Michigan."
Women's March, which has been organizing organizing major women's rights demonstrations in recent years, called for a nationwide rally defending abortion rights for April 15.
A.Malone--AMWN